Photo by Anna Pelzer / Unsplash. Illustrative stock photograph; no endorsement or medication use is implied.
Understanding the change and deciding what to discuss
By David L. Carpenter, BSN, RN | Health Content Works
Evidence checked: October 17, 2026.
For a while, food took up less room in your day. You could finish a meal and move on. Now you are thinking about your next snack again, and a familiar worry follows: Is the medication still working?
That question deserves a useful answer. But first, it helps to describe what has actually changed. Wanting lunch, craving a particular food, and being unable to concentrate because thoughts about eating keep interrupting you are different experiences. They can also happen together.
This article is for adults using Wegovy or Zepbound injections. Its purpose is to help you explain returning hunger or intrusive food thoughts without turning them into a diagnosis, a personal failure, or a reason to change your prescription yourself.
Start with what you mean by hungry
You do not need the perfect medical term. Try describing the experience in ordinary language:
- “I feel ready for a meal sooner than I used to.”
- “I keep wanting one particular food, even after dinner.”
- “Thoughts about eating keep interrupting work, and it is hard to focus.”
- “Once I start eating, I sometimes feel unable to stop.”
Those examples describe experiences, not diagnoses or a screening test. Physical hunger, a craving, repeated food thoughts, and feeling unable to control eating can overlap, but they are not the same. Feeling unable to control eating deserves its own discussion.
People often use “food noise” to describe persistent, intrusive thoughts about food. Researchers are studying the concept, but its boundaries and clinical meaning remain debated. A 2026 scholarly commentary highlights overlap with cravings and food preoccupation, and cautions that measurement tools still have limits. It is a discussion of the evidence, not a treatment trial. [1]
For our purposes, the useful question is how the experience affects your day. Looking forward to dinner is different from repeatedly losing your place in a conversation because you cannot stop thinking about food. A label should help you explain that difference, not make every food thought feel like a problem.
What the research can tell us
A randomized, placebo-controlled study tested weekly semaglutide injections in 72 adults with obesity for 20 weeks. At week 20, participants receiving semaglutide reported less hunger, better control of eating, and fewer or weaker cravings than those receiving placebo. The dose was gradually increased to 2.4 mg. [2]
This was a small, single-center study that excluded people with diabetes-range blood test results. Appetite ratings were secondary outcomes; the eating-control questionnaire was exploratory. Novo Nordisk funded the study, and several authors were company employees. [2]
These findings concern appetite during a small, 20-week study. The trial did not test returning food thoughts months later or determine how to adjust treatment when appetite changes. It did not study tirzepatide, the medicine in Zepbound, so its findings should not be applied to both products. [2]
Stopping treatment is a separate question. In the STEP 1 extension, a subset of 327 participants was followed after semaglutide and structured lifestyle support ended at week 68. Over the following year, those previously receiving semaglutide regained, on average, about two-thirds of their prior weight loss. This was an observational follow-up, not a new randomized comparison of stopping versus continuing. [8]
In SURMOUNT-4, participants who completed 36 weeks of tirzepatide were randomized to continue it or switch to placebo for 52 weeks. Those switched to placebo regained weight on average; those continuing lost more. Lifestyle counseling continued in both groups. [9] These studies concern weight maintenance. They do not establish why hunger returns during continued treatment, an individual food-noise timeline, or a dose-adjustment plan. [8,9]
Returning hunger is information to assess
“The medicine stopped working” is a conclusion. “I am hungry again before dinner” is an observation. Starting with the observation leaves room to investigate instead of deciding the answer before the appointment.
Medication benefit is broader than how little you want to eat. NIDDK describes treatment decisions in terms of benefits, side effects, other health conditions and medicines, and cost. Continuing treatment can be appropriate when it helps a person maintain a health improvement. [3] Your prescriber can assess those factors alongside the appetite change.
A change in hunger also is not the same thing as a weight-loss plateau. One describes an experience; the other describes a weight pattern over time. If the scale has stalled too, bring up both concerns. HCW’s separate plateau article addresses that question without making this another guide to weighing and tracking.
Look at the circumstances around the change
Before reaching for a new rule, consider a few ordinary details. Are you getting through the workday on very little food? Has nausea made meals difficult? Are you sleeping differently, working longer hours, or taking a new medicine? These are details to discuss, not proof of why your appetite changed.
If you notice the change near the end of the injection week, describe when it happens. Timing alone does not tell you that the dose is wrong. It also does not justify shortening the interval between injections. Both Medication Guides say to use the medicine as your healthcare provider directs. Ask your prescriber or pharmacist about concerns. [4,5]
Mention any missed doses, supply interruption, storage concern, or uncertainty about using the device. A pharmacist can review the instructions for the exact product you have. There is no single missed-dose or restart rule that applies to both medicines. [4,5]
The practical aim is to find the part of the plan that needs attention. If you cannot eat comfortably, that deserves help. If your schedule leaves no reasonable meal break, tell your care team what a typical shift looks like. More restriction is not automatically the answer to either problem. For practical eating guidance, see Low appetite and small meals.
Do not turn eating into a test of treatment
You do not have to prove that treatment works by seeing how long you can avoid food. NIDDK notes that, for some people, skipping meals or not eating enough may contribute to binge eating. That does not explain everyone’s hunger, but it is a reason to avoid responding to distress with increasingly restrictive rules. [6]
If food thoughts are upsetting or you feel out of control while eating, say so directly. Eating unusually large amounts in a short period, feeling unable to stop, eating secretly because of embarrassment, and distress afterward are concerns worth discussing. A clinician can assess whether an eating disorder is present; hunger or a craving alone does not establish one. [6]
A registered dietitian or a clinician experienced in eating concerns may help assess what support fits. Our goal here is a useful conversation, not a plan to suppress every appetite signal or a promise that a particular snack, supplement, or higher dose will solve the problem.
An example of a more useful conversation
Consider Jordan, a fictional reader. Jordan says, “The medicine is wearing off.” Asked to explain, Jordan describes eating very little during work and then spending the evening thinking about food.
A clearer starting point might be: “For the past two weeks, I have been thinking about food through most of the evening. My work meals have been small because I feel full quickly. I have not changed my dose. Can we review whether I am eating enough, what the medication is doing, and whether I need additional support?”
That example does not diagnose Jordan’s situation. It gives the clinician something concrete to explore. Your own description might be completely different. You can explain what happens, how often it happens, and what it keeps you from doing without collecting a month of records first.
When symptoms need prompt attention
Do not dismiss sudden hunger with shaking, sweating, dizziness, or confusion as food noise. These can be signs of low blood sugar. [4,5] Wegovy’s guide highlights risk in people with type 2 diabetes, especially with insulin or a sulfonylurea. Zepbound’s guide warns that risk may be higher with medicines such as insulin or a sulfonylurea. If you have a glucose-checking and treatment plan, follow it. Seek urgent help if you cannot safely treat yourself or symptoms are severe. Loss of consciousness or a seizure requires emergency help. [7] Hunger alone does not diagnose hypoglycemia. [4,5,7]
Both Medication Guides instruct you to stop the medicine and contact your provider right away for severe abdominal pain that persists, sometimes extending to the back, with or without nausea or vomiting. This is the warning for possible pancreatitis. They also say to contact your provider promptly if nausea, vomiting, or diarrhea does not go away, because dehydration can lead to kidney problems. Severe symptoms or an inability to keep fluids down warrant urgent medical advice. [4,5]
These safety instructions are separate from ordinary questions about appetite. Do not raise doses, add injections, or take a medication break to experiment with hunger. Use your prescribed instructions and ask for a treatment review. [4,5]
Leave with a question you can act on
Ask your clinician: “Does this sound like ordinary hunger, an intake problem, troublesome food preoccupation, or something else? How will we assess whether treatment is still helping? What should we do next, and when should I check back?”
You do not need to wait for weight regain before discussing a change that is troubling you. The point is to understand what is happening and agree on an appropriate next step. Feeling hungry is something you can talk about openly. It is not a character flaw.
General educational information, not individualized medical advice. Prepared with AI assistance and reviewed by David L. Carpenter, BSN, RN.
Sources
Focused review, not a systematic review. Source 1 was assessed from its indexed abstract.
[1] Brewis A, et al. Food noise: Conceptual, methodological, and ethical considerations. Appetite. 2026;226:108700. Published online July 2, 2026. doi:10.1016/j.appet.2026.108700. Commentary; abstract accessed.
https://pubmed.ncbi.nlm.nih.gov/42392316/
[2] Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021;23:754–762. doi:10.1111/dom.14280. Publisher full text accessed.
https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14280
[3] NIDDK. Prescription Medications to Treat Overweight and Obesity. General treatment principles; not a product-specific dosing protocol.
[4] Novo Nordisk. Wegovy Medication Guide. DailyMed, combined injection and tablet record. This article applies the injection instructions only. Guide revised June 2026; accessed October 17, 2026.
https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[5] Eli Lilly. Zepbound Medication Guide. DailyMed. Guide revised August 2026; accessed October 17, 2026.
https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[6] NIDDK. Symptoms and Causes of Binge Eating Disorder. Last reviewed May 2021. General eating-disorder guidance, not GLP-1-specific evidence.
https://www.niddk.nih.gov/health-information/weight-management/binge-eating-disorder/symptoms-causes
[7] NIDDK. Low Blood Glucose Hypoglycemia. Last reviewed July 2021. General diabetes guidance.
[8] Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022;24(8):1553–1564. doi:10.1111/dom.14725.
https://doi.org/10.1111/dom.14725
[9] Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331:38–48.
https://doi.org/10.1001/jama.2023.24945
Leave a Reply